Renal Biomarkers Market

Renal Biomarkers Market, by Biomarker Type (Functional Biomarker (Serum Creatinine, Serum Cystatin C, Urine Albumin), Up-Regulated Proteins (Neutrophil gelatinase-associated lipocalin, Kidney injury molecule 1, Interleukin 18), Others, By Technique (Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay, Liquid Chromatography-Mass Spectrometry), By End User (Diagnostic Labs, Outpatient Clinics, Research Centers, Hospitals), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

A biomarker (biologic marker) is a measurable indicator of a specific biological state, particularly one relevant to the risk for, presence of, or stage of a disease. Clinically, biomarkers can be used to screen for, diagnose, or monitor the activity of diseases as well as guide molecularly targeted therapy or assess therapeutic response. Renal biomarkers are biological indicators that help in the diagnosis and monitoring of kidney function and injury. These biomarkers include serum creatinine, blood urea nitrogen, cystatin C, and various urine biomarkers such as albumin, protein, and kidney injury molecule-1 (KIM-1). These biomarkers can be used to identify the early stages of kidney disease, monitor the progression of kidney disease, and predict the risk of kidney injury in patients undergoing medical procedures or taking certain medications. They provide valuable information for healthcare professionals to manage and treat patients with kidney disease, helping to reduce the morbidity and mortality associated with this condition.

Market Dynamics

The key market players are focusing on the adoption of growth strategies such as product launches which is attributed to the growth of the global renal biomarker market. The renal biomarker market is influenced by several factors such as the increasing prevalence of chronic kidney diseases (CKD), diabetes, and hypertension; the growing aging population; and the rising demand for point-of-care testing. The market is also driven by technological advancements in renal biomarker detection techniques, the increasing number of government initiatives and programs to promote renal health, and the rise in research and development investments in the field. For instance, in April 2021, Renalytix AI plc., a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, announced that it had entered into an exclusive option agreement with Joslin Diabetes Center, diabetes research, clinical care, and education organization dedicated to the prevention, treatment, and research towards a cure for diabetes, for patent filings on certain additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX in vitro prognostic platform. These novel biomarkers have the potential to provide additional clinical utility for understanding early disease progression and risk of kidney failure, therapeutic response, and the mechanistic pathways of kidney disease beyond the inflammatory and tubular injury markers that are currently captured by KidneyIntelX.

Key features of the study:

• This report provides an in-depth analysis of the global renal biomarker market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global renal biomarker market based on the following parameters–Company highlights, product portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Beckman Coulter, Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Bioporto Diagnostics A/S, Astute Medical, Inc., Randox Laboratories, Sphingo Tec GmbH, Siemens Healthineers AG, Eli Lilly and Company, and Novartis AG.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global renal biomarker market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global renal biomarker market

Detailed Segmentation:

• Global Renal Biomarkers Market, By Biomarker Type:
• Functional Biomarker
• Up-Regulated Proteins
• Others
• Global Renal Biomarkers Market, By Technique:
• Enzyme Linked Immunosorbent Assay
• Particle-enhanced Turbidimetric Immunoassay
• Calorimetric Assay
• Chemiluminescent Enzyme Immunoassay
• Liquid Chromatography-Mass Spectrometry
• Global Renal Biomarkers Market, By End User:
• Diagnostic Labs
• Outpatient Clinics
• Research Centers
• Hospitals
• Global Renal Biomarkers Market, By Region:
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Beckamn Coulter, Inc.
• Thermo Fisher Scientific, Inc.
• Abbott Laboratories
• Bioporto Diagnostics A/S
• Astute Medical, Inc.
• Randox Laboratories
• Sphingo Tec GmbH
• Siemens Healthineers AG
• Eli Lilly and Company
• Novartis AG